# Revenue Differences Between Top-Selling Small-Molecule Drugs and Biologics in Medicare

## TL;DR

This study compares how much money drug makers made from top-selling small-molecule drugs and biologics in Medicare over 9 to 13 years after FDA approval.

## Contribution

It provides a revenue comparison of drug types eligible for Medicare price negotiations over an extended post-approval period.

## Key findings

- Revenues were analyzed for 9 to 13 years after FDA approval for eligible drugs.
- The study covers negotiation-eligible products approved between 2012 and 2022.
- It highlights differences in revenue generation between small-molecule drugs and biologics.

## Abstract

This study compares the revenues earned by manufacturers 9 vs 13 years following US Food and Drug Administration approval for negotiation-eligible products from 2012 to 2022.